Imiquimod (Aldara cream).
نویسنده
چکیده
IMIQUIMOD CREAM: INDICATION Imiquimod (AldaraTM, 3M Pharmaceuticals, St. Paul, MN) is an immune-response modifier. In the United States, it is currently indicated for the treatment of external anogenital warts. Available in a 5% cream, it is applied by the patient to the warts and adjacent skin three times a week (e.g., Monday, Wednesday, and Friday or Tuesday, Thursday, and Saturday) for up to 16 weeks until warts are gone.
منابع مشابه
Acantholytic Pityriasis Rubra Pilaris Associated with Imiquimod 3.75% Application
Imiquimod is an immunomodulator with both antitumor and antiviral properties. It is currently available in two cream formulations as Aldara (imiquimod 5%) and the newly approved Zyclara (imiquimod 3.75%). Imiquimod has been associated with localized erythema, crusting, and scaling at the site of application. However, more severe generalized skin eruptions including erythema multiforme, psoriasi...
متن کاملTreatment of actinic cheilitis with imiquimod 5% and a retractor on the lower lip: clinical and histological outcomes in 5 patients.
Imiquimod 5% (Aldara, 3M Healthcare Ltd.) is a topically applied immune response modifier used in the treatment of superficial basal cell carcinoma, actinic keratosis, and genital warts. We reviewed the casenotes of 5 patients with histologically confirmed dysplastic lower lips who had been treated with topical imiquimod. Each patient was provided with a specially designed lower lip retractor t...
متن کاملSelf-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.
OBJECTIVE To compare the safety and effectiveness of 5% and 1% imiquimod cream with vehicle cream in the treatment of external anogenital warts. DESIGN Randomized, double-blind, placebo-controlled comparison that evaluated patients for total clearance of their warts. Patients who experienced total clearance were evaluated for recurrence in a 12-week follow-up. SETTING Eleven ambulatory offi...
متن کاملClinical Medicine Reviews in Oncology
Imiquimod 5% cream (Aldara) was approved by the Food and Drug Administration for the treatment of non-facial superficial basal cell carcinomas (sBCC) in 2004 and has become one of the most commonly used topical treatments for this variant of basal cell carcinoma. Application of the cream once a day, 5 days per week for 6 weeks has demonstrated a clinical and histological cure rate approximating...
متن کاملCytokine dermatitis and febrile seizure from imiquimod.
Cytokine dermatitis is a well-known and common clinical adverse effect of imiquimod 5% cream (Aldara, 3M). Data from initial Phase III clinical trials reveal a minority of study drug patients experience systemic adverse effects, including fever, arthralgia, headache, myalgia, and lymphadenopathy. These adverse effects are caused, presumably, from increased absorption of study drug over the area...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Infectious Diseases in Obstetrics and Gynecology
دوره 6 شماره
صفحات -
تاریخ انتشار 1998